AnaptysBio (ANAB) Price Target Increased to $162.00 by Analysts at SunTrust Banks

AnaptysBio (NASDAQ:ANAB) had its price objective raised by SunTrust Banks from $115.00 to $162.00 in a research report released on Thursday. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other brokerages also recently weighed in on ANAB. Credit Suisse Group set a $135.00 target price on AnaptysBio and gave the company an outperform rating in a research note on Tuesday, January 23rd. Robert W. Baird restated a buy rating and set a $144.00 target price (up previously from $81.00) on shares of AnaptysBio in a research note on Friday, January 19th. ValuEngine upgraded AnaptysBio from a sell rating to a hold rating in a research note on Friday, February 2nd. Zacks Investment Research downgraded AnaptysBio from a buy rating to a hold rating in a research note on Tuesday, January 2nd. Finally, Royal Bank of Canada increased their target price on AnaptysBio to $108.00 and gave the company an outperform rating in a research note on Monday, December 18th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $107.11.

Shares of AnaptysBio (ANAB) traded down $4.91 during midday trading on Thursday, hitting $119.86. The stock had a trading volume of 274,800 shares, compared to its average volume of 311,324. The company has a current ratio of 10.77, a quick ratio of 10.77 and a debt-to-equity ratio of 0.09. AnaptysBio has a fifty-two week low of $18.15 and a fifty-two week high of $132.46.

A number of large investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in AnaptysBio by 104.1% during the 4th quarter. BlackRock Inc. now owns 1,393,305 shares of the biotechnology company’s stock valued at $140,334,000 after purchasing an additional 710,574 shares during the period. OppenheimerFunds Inc. bought a new stake in shares of AnaptysBio in the 4th quarter worth approximately $106,701,000. Perceptive Advisors LLC lifted its position in shares of AnaptysBio by 3.2% in the 3rd quarter. Perceptive Advisors LLC now owns 982,269 shares of the biotechnology company’s stock worth $34,330,000 after acquiring an additional 30,000 shares during the period. Citadel Advisors LLC bought a new stake in shares of AnaptysBio in the 3rd quarter worth approximately $20,406,000. Finally, Farallon Capital Management LLC lifted its position in shares of AnaptysBio by 128.0% in the 4th quarter. Farallon Capital Management LLC now owns 561,000 shares of the biotechnology company’s stock worth $56,504,000 after acquiring an additional 315,000 shares during the period. Hedge funds and other institutional investors own 76.23% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “AnaptysBio (ANAB) Price Target Increased to $162.00 by Analysts at SunTrust Banks” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/16/anaptysbio-anab-price-target-increased-to-162-00-by-analysts-at-suntrust-banks.html.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply